Live30 webinars are 30-minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
The remarkable success enjoyed by cell-based therapies, particularly CAR T therapies, has propelled manufacturers and the financial sector to invest tremendous effort and capital in this space. This acceleration has led to major bottlenecks in manufacturing capacity and shortage of raw materials, both of which were exaggerated during the pandemic. The industry’s frenzied push to resolve these challenges have kept the build vs. buy conversation center stage.
The recent market downturn and its inevitable economic impact has re-ignited the build vs. buy debate. Many pharma and biotech companies are re-thinking their strategies, including the use of their capital to strengthen their pipeline assets rather than building out their own cell therapy manufacturing facilities.
Given these developments, it is vital that cell therapy developers and their investors revisit the build vs buy strategy, assess the pros and cons, and design new models to make these life-changing therapies a reality.
This webinar will showcase: